Pay in 4 interest-free payments of $6.92 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Retatrutides development timeline suggests potential availability within the next few years, assuming successful trial completion and regulatory approval
The point is that a triple agonist needs careful evaluation before broad use
Provides a summary of the efficacy and safety profiles of once-weekly GLP-1 receptor agonists, offering insights into the long-term use of Semaglutide and its potential application in chronic conditions like IBS
We're excited to continue studying GIP/GLP-1 RA and hope to add it to our wide range of therapies for people with diabetes." The safety and efficacy of Lilly's GIP/GLP-1 RA are being studied further in a large phase 3 clinical program that will be referred to as the SURPASS program
